Eric Pujade-Lauraine

13PUBLICATIONS
146CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jan 29, 2026
Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor.

Hyun-Woong Cho, Jeong-Yeol Park, Myong Cheol Lim

|Jan 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Félix Blanc-Durand, Benoit You, Yahia Adnani

|Nov 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

Claudia Marchetti, Gwenael Ferron, Olivier Colomban

|Jul 02, 2025
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.

Yann Christinat, Intidhar Labidi-Galy, Liza Ho

|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium.

Nicole Concin, Ioana Braicu, Pierre Combe

|Apr 26, 2024
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy.

Elisa Yaniz-Galende, Qinghe Zeng, Juan F Bejar-Grau

Pageof 3

Frequent Collaborators

10 joint publications

Isabelle Ray-Coquard

5 joint publications

Florence Joly

4 joint publications

Ignace Vergote

3 joint publications

Keiichi Fujiwara